Skin-specific regulation of SREBP processing and lipid biosynthesis by glycerol kinase 5
The recessive N-ethyl-N-nitrosourea–induced phenotype toku is characterized by delayed hair growth, progressive hair loss, and excessive accumulation of dermal cholesterol, triglycerides, and ceramides. The toku phenotype was attributed to a null allele of Gk5, encoding glycerol kinase 5 (GK5), a sk...
Saved in:
Published in | Proceedings of the National Academy of Sciences - PNAS Vol. 114; no. 26; pp. E5197 - E5206 |
---|---|
Main Authors | , , , , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
United States
National Academy of Sciences
27.06.2017
|
Series | PNAS Plus |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | The recessive N-ethyl-N-nitrosourea–induced phenotype toku is characterized by delayed hair growth, progressive hair loss, and excessive accumulation of dermal cholesterol, triglycerides, and ceramides. The toku phenotype was attributed to a null allele of Gk5, encoding glycerol kinase 5 (GK5), a skin-specific kinase expressed predominantly in sebaceous glands. GK5 formed a complex with the sterol regulatory element-binding proteins (SREBPs) through their C-terminal regulatory domains, inhibiting SREBP processing and activation. In Gk5toku/toku
mice, transcriptionally active SREBPs accumulated in the skin, but not in the liver; they were localized to the nucleus and led to elevated lipid synthesis and subsequent hair growth defects. Similar defective hair growth was observed in kinase-inactive GK5 mutant mice. Hair growth defects of homozygous toku mice were partially rescued by treatment with the HMG-CoA reductase inhibitor simvastatin. GK5 exists as part of a skin-specific regulatory mechanism for cholesterol biosynthesis, independent of cholesterol regulation elsewhere in the body. |
---|---|
Bibliography: | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 Author contributions: D.Z., W.T., X.Z., and B.B. designed research; D.Z., W.T., L. Su, L. Sun, J.H.C., Z.Z., K.-w.W., X.Z., M.C., X.L., M.T., and J.M.C.-P. performed research; D.Z., W.T., X.Z., J.M.C.-P., S.H., and B.B. analyzed data; and D.Z., A.R.M., E.M.Y.M., and B.B. wrote the paper. 1Present address: Group II, Frontier Research Laboratories, R&D Division, Daiichi Sankyo Co., Ltd., Shinagawa-ku, Tokyo 140-8710, Japan. 2Present address: Waters Corporation, Milford, MA 01757. Reviewers: D.L.K., National Institutes of Health; and C.C.Z., Theodor Fontane Medical University of Brandenburg, Dessau Medical Center. Contributed by Bruce Beutler, May 9, 2017 (sent for review March 30, 2017; reviewed by Daniel L. Kastner and Christos C. Zouboulis) |
ISSN: | 0027-8424 1091-6490 |
DOI: | 10.1073/pnas.1705312114 |